Madam Therapeutics, a Leiden, The Netherlands-based biotech company that is developing a novel class of antibiotics inspired by the defense mechanisms of the human body, closed a €1.1M first financing round.
Backers included a network of European business angels facilitated by Ekoy Investment Partners, De Investeerders Club and Investormatch.
The company intends to use the funds to accelerate the clinical development of its lead candidate SAAP-148 for the treatment of broad spectrum multi-drug resistant infections.
Led by Dr. Remko van Leeuwen, CEO, Madam Therapeutics is developing Synthetic Anti-Microbial and Anti-Biofilm Peptides (SAAPs) to combat resistant bacterial infections. Its SAAPs combine killing of (resistant) bacteria and limited likelihood of emerging resistance.
To date, the company and her academic partners have raised a substantial amount of non-dilutive funding for the development of a family of over 300 unique SAAPs and a pipeline of SAAP based products for multiple infectious diseases.
Madam Therapeutics is currently actively fundraising for the next stages of clinical trials and broadening its pipeline of products, besides looking for co-development partners for further development and commercialization of its products.